Kiniksa Pharmaceuticals (NASDAQ:KNSA) announces “early
evidence” of treatment response in COVID-19-related pneumonia and
hyperinflammation with antibody mavrilimumab. Shares up 42% premarket.
Vaccinex (NASDAQ:VCNX) inks agreements for
$16.5M in financing via at-the-market stock sales. It is working with
clinical investigators to accelerate the SIGNAL study evaluating
pepinemab in Huntington’s disease (206 of 265 subjects have completed 18
months’ treatment). Shares up 9% premarket.
BioCorRx (OTCQB:BICX) does not expect any delays in its preclinical studies of BICX102. Human studies should launch in early 2021.
Applied BioSciences (OTCQB:APPB) has begun shipping CE-Mark’d Coronavirus Test Kits in the U.S. (detects antibodies in finger-stick samples in under 15 minutes).
Anavex Life Sciences (NASDAQ:AVXL): clinical trials
in Rett syndrome, Alzheimer’s and Parkinson’s are continuing. Topline
data from a Phase 2 in Parkinson’s dementia to be released mid-year.
Contingency plans in place to allow remote/virtual assessment in
Alzheimer’s and Parkinson’s studies (already in place in Rett studies).
Xenon Pharmaceuticals (NASDAQ:XENE) has extended the
expected release of topline data from the Phase 2b X-TOLE study
(XEN1101) to H1 2021 due to slower enrollment. It has sufficient cash to
fund operations into 2022.
Health Catalyst (NASDAQ:HCAT) has launched its
initial COVID-19 solutions (Patient and Staff Tracker, Public Health
Surveillance and Staff Augmentation Support) and is launching a COVID-19
Registry, Dashboard and Capacity Planning Tool.
https://seekingalpha.com/news/3556764-covidminus-19-related-announcements-healthcare
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.